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Abstract  
Background: Cytomegalovirus (CMV) infection exacerbates ulcerative colitis (UC) 
refractory to immunosuppressive therapies. However, the underlying UC remained 
active in some UC patients, despite the fact that CMV-DNA in colonic mucosa became 
negative after antiviral therapy. Therefore, new therapeutic strategies for UC patients 
concomitant with CMV infection in mucosa are required.  
Aims: The aim of this study was to evaluate the effect and safety of 
granulocyte-monocyte adsorption apheresis (GMA) in UC patients positive for CMV 
infection after antiviral therapy. 
Methods: From October 2003 to December 2008, 64 patients with UC refractory to 
immunosuppressive therapies (IMT), including steroids and immunomodulators, were 
enrolled in this retrospective, observational, multicenter study, which was reviewed and 
approved by the Institutional Review Board of Kyoto University. CMV infection was 
investigated by three methods (histologic examination, CMV antigenemia, and 
polymerase chain reaction). We investigated clinical outcomes of GMA and IMT after 
2weeks of treatment with ganciclovir.  
Results: Thirty-one (48.4%) of 64 patients with UC refractory to IMT were positive for 
CMV. Of 31 patients, 4 (12.9%) underwent colectomy. Twenty-seven patients (87.1%) 
underwent antiviral therapy. Seven of 27 patients achieved remission following antiviral 
therapy alone. Of the remaining 20 patients that did not achieve remission despite the 
disappearance of CMV-DNA, 11 and 9 patients were treated with additional GMA 
(GMA group) and IMT (IMT group), respectively. Nine of 11 patients (GMA group) 
achieved remission and 2 underwent colectomy. Four of 9 patients (IMT group) 
achieved remission and 5 underwent colectomy. CMV-DNA was not detected in 11 
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patients after GMA, but it was detected again in all 5 patients of the IMT group, that 
underwent colectomy. Total colectomy rate in UC patients positive for CMV was 35.5% 
(11/31). In addition, colectomy-free survival in the CMV relapse (+) group was 
estimated to be 12.9% at 65 months, while that in the CMV relapse (-) group was 
estimated to be 100% at 60 months. 
Conclusion: The colectomy ratio tends to be high in refractory UC patients with 
recurrent CMV reactivation or infection. Therefore, GMA might be a safe and effective 
treatment for UC patients positive for CMV because it does not induce avoiding CMV 
reactivation. 
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Introduction  
Cytomegalovirus (CMV) infection is considered to be an important exacerbating factor 
in patients with ulcerative colitis (UC) [1, 2]. Therefore, accurate and rapid diagnosis of 
CMV infection is critical for treatment for UC patients refractory to immunosuppressive 
therapies (IMT). We previously reported the usefulness of quantitative real-time 
polymerase chain reaction using colonic mucosa (mucosal PCR) for accurately 
diagnosing CMV infection in patients with UC refractory to IMT [3,4]. Based on the 
results of mucosal PCR for CMV-DNA in inflamed mucosa, we applied either antiviral 
therapy or modulating IMT to UC patients [3,4]. However, colonic inflammation 
remained active in some UC patients, even in those whose colonic mucosa became 
CMV-DNA negative after antiviral therapy. Domènech et al reported that CMV disease 
in UC patients occurs in the presence of colonic mucosal inflammation and ongoing 
IMT [5]. In addition, the results of experiments in a mouse model of colitis suggested 
that the underlying CMV infection alters mucosal immunity, potentially increasing the 
tendency of CMV-infected hosts to develop colitis [6]. Therefore, to establish 
anti-inflammatory therapy without reactivating CMV in UC patients with concomitant 
CMV infection is a very important issue.  
It was recently established in Japan that granulocytapheresis (GCAP) using an 
Adacolumn (Japan Immunoresearch Laboratories, Takasaki, Japan) is safe and effective 
for active UC [7]. This apheresis column is filled with cellulose diacetate carriers that 
selectively adsorb granulocytes and monocytes/macrophages. Shimoyama et al. 
reported that a high remission rate was achieved in UC patients following GCAP 
therapy [5]. GCAP is a promising option for patients with UC refractory to conventional 
therapy, including prednisolone (PSL).  
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In general, after primary CMV infection, CMV persists within the host, in whom 
peripheral and bone marrow monocytes constitute a major site of viral latency. The 
differentiation of CMV latent monocytes into tissue macrophages due to granulocyte 
macrophage colony-stimulating factor and proinflammatory cytokines such as tumor 
necrosis factor (TNF)-α leads to CMV replication and CMV reactivation [8]. A recent 
in vitro study showed that CMV could force monocytes to acquire an M1 
proinflammatory phenotype and differentiate into long-lived macrophages [9]. CMV- 
infected monocytes with the M1 phenotype induce cytokine expression of interleukin 
(IL)-6, TNF-α, and IL-1β, which might be involved in colonic inflammation of patients 
with inflammatory bowel disease (IBD). Considering the mechanism of CMV 
reactivation, granulocyte-monocyte adsorption apheresis (GMA) may be effective for 
UC patients concomitant with CMV infection, because it can remove granulocytes and 
monocytes/macrophages in which CMV infects latently and reactivates. Also, because 
treatment with steroids and IMT can be avoided, GMA might not affect the immune 
response to CMV reactivation.  
In this study, we first evaluated whether or not flare-ups of UC positive for CMV can 
improve after antiviral therapy alone. Next, we evaluated the effect and safety of GMA 
in comparison with IMT as additional therapies in case the underlying UC remained 
active even after antiviral therapy. 
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Materials and Methods  
Patients: From October 2003 to December 2008, 64 patients with UC refractory to IMT, 
including steroids and immunomodulators, were enrolled in this retrospective, 
observational, multicenter study, which was reviewed and approved by the Institutional 
Review Board of Kyoto University. 
The diagnosis of UC was based on clinical, endoscopic, radiologic, and histological 
parameters. Fecal bacterial culture yielded no specific pathogens in any of the patients. 
All patients had been treated with IMT, and had active UC defined as moderate to 
severe using the disease activity index (DAI) criteria, with a score greater than 6 points. 
We defined patients with refractory UC as follows: (1) patients who had ongoing active 
disease despite continuous acute-phase treatment with systemic corticosteroids in daily 
doses of more than 1 mg PSL equivalent per kilogram body weight or administration of 
tacrolimus with optimal trough level to induce remission for at least 14 days; (2) 
patients who had chronic active UC for more than 6months despite taking more than 
10mg PSL; and (3) patients who had relapsed, irrespective of azathioprine treatment for 
at least 3 months.  
Assessment of endoscopic severity: Endoscopic severity of UC was based on 
endoscopic findings and scored from 1 to 4 according to Matts grade [10] as follows:  
normal=1; mild granularity and edema=2; marked granularity and edema, and 
spontaneous bleeding=3; and severe ulceration=4.  
Histopathology: Colonic biopsies were fixed in formalin, embedded in paraffin, and 
stained with hematoxylin and eosin, and immunohistochemistry was performed using 
anti-CMV monoclonal antibodies (Dako Cytomation, Kyoto, Japan) [3,4].  
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CMV antigenemia: The antigenemia assay was performed using a monoclonal 
antibody (C7HRP or C10C11) against a CMV structural protein of the 65kDa 
lower-matrix phosphoprotein (pp65).  
Quantitative real-time PCR: DNA for real-time PCR assay was extracted from 
inflamed mucosa obtained from patients at endoscopic examination using a QIAamp 
DNA Blood Mini Kit (QIAGEN, Tokyo, Japan) according to the manufacturer’s 
instructions. The assay was performed using an ABI Prism 7700 Sequence Detector 
System (Perkin Elmer Applied Biosystems, Foster City, CA) as descri ed previously  
The oligonucleotide primers used for CMV-DNA amplification  ere constructed to 
detect the immediate early gene  The upstream primer  as 
  -GACTAGTGTGATGCTGGCCAAG-  and the do nstream primer  as 
  -GCTACAATAGCCTCTTCCTCATCTG-  . The  -car o yfluorescein-la eled pro e 
 as   - AGCCTGAGGTTATCAGTGTAATGAAGCGCC-  . The PCR conditions were 
incubation at 95 °C for 10 minutes, 50 cycles of 95 °C for 15 seconds, followed by 
incubation at 62 °C for 1 minute. Cases in which the CMV-DNA copy number was over 
10 copies/μg DNA  ere defined as positive for CMV [3, 4].  
Diagnosis of CMV infection: Cases in which CMV was detected by at least one of 
these methods (histological examination, CMV antigenemia, and quantitative real- time 
PCR) were defined as positive for CMV. 
Treatment: All patients defined as positive for CMV were hospitalized at the time of 
initiation of ganciclovir (DENOSINE○R , Mitsubishi Tanabe Pharma, Osaka, Japan) . 
Ganciclovir (5mg/kg body weight) was intravenously administered twice a day for 2 
weeks. If patients did not complete the 2weeks of ganciclovir treatment due to the 
disease activity, surgical treatment was performed. After starting ganciclovir, tacrolimus 
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and azathioprine were completely withdrawn and corticosteroids were tapered by 
reducing the dose 5 to 10 mg/week (more slowly in patients with high disease activity) 
and completely withdrawn, if possible. After patients completed 2weeks treatment with 
ganciclovir, disease activity and CMV status were evaluated. If a patient who became 
negative for CMV after 2weeks antiviral therapy did not achieve clinical remission, the 
patient received additional GMA or IMT to induce remission. 
Assessment: As a first evaluation of the therapeutic effect, we investigated whether or 
not UC patients went into remission following antiviral therapy alone. As a second 
evaluation of the therapeutic effect, including colectomy-free survival, the effect of 
additional GMA in patients with UC who did not achieve remission after antiviral 
therapy was compared with that of additional IMT. 
Statistical Analysis: Categorical and continuous data were compared using a two-tailed 
Fisher exact test and Mann-Whitney U test. A P value of less than 0.05 was considered 
statistically significant. Colectomy-free survival was assessed using the Kaplan-Meier 
method. 
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Results  
Demographic and clinical characteristics: From October 2003 to December 2008, we 
evaluated 64 patients with UC refractory to IMT including corticosteroids and 
immunomodulators. CMV-DNA was detected in inflamed mucosa of 31 patients 
(48.4%) based on mucosal PCR. On the other hand, CMV antigenemia and histological 
examination were positive in only 7 (10.9%) and 3 (4.7%) of the 64 patients with UC 
refractory to IMT, respectively. Moreover, none of the patients negative for CMV-DNA 
in the colonic mucosa was positive for either CMV antigenemia or histological 
examination. The clinical characteristics of these patients were as follows. Mean age of 
the 31 patients was 43.5±18.7 years (range; 17-80 years) and the mean DAI score was 
9.9±1.7. The extent of disease was proctitis (3.2%), left-sided colitis (35.5%), and 
pancolitis (61.3%). The mean Matts grade was 3.2±0.8. Of the 31 patients, 27 (87.1%) 
had been treated with corticosteroids, 8 (25.8%) with azathioprine, 8 (25.8%) with 
tacrolimus, and 4 (12.9%) with cytapheresis when patients were diagnosed as CMV- 
positive. 
 
Effect of antiviral therapy on UC patients positive for CMV: Of 31 patients positive 
for CMV, 4 patients (12.9%) underwent colectomy before finishing 2weeks treatment 
with ganciclovir therapy due to the disease activity. The remaining 27 patients (87.1%) 
were treated with ganciclovir. CMV-DNA in colonic mucosa became negative in all 
patients that received antiviral therapy. Seven patients (25.9%) went into remission 
following antiviral therapy only. We evaluated the difference in age, DAI score, disease 
extent and Matts grade of endoscopic severity between UC patients who achieved 
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remission following antiviral therapy alone and those who did not. As shown in Table 1, 
there was no significant difference in the clinical parameters between UC patients who 
went into remission after antiviral therapy alone and those who did not. Moreover, the 
initial treatment did not affect the result of antiviral therapy, because all UC patients 
positive for CMV-DNA became negative for CMV-DNA after antiviral therapy. 
 
Effect of GMA or IMT on UC patients after antiviral therapy: In 20 (74.1%) of 27 
UC patients, the underlying UC remained active, despite the disappearance of 
CMV-DNA in the colonic mucosa after treatment with antiviral therapy (Figure 1). 
Clinical parameters of both GMA and IMT groups are shown in Table 1. Eleven (55%) 
of the 20 patients were treated with additional GMA (GMA group). Six (54.5%) of them 
achieved remission, while 5 (45.5%) patients did not. Finally, 2 of these 5 patients 
required colectomy. Interestingly, in all patients treated with GMA, CMV-DNA was not 
detected in the colonic tissue after GMA treatment. On the other hand, 9 (45.0%) of the 
20 patients in whom the underlying UC remained were treated with additional IMT 
(IMT group). Eight of the 9 patients (88.9%) were treated with tacrolimus, and 
remaining 1 patient (11.1%) was treated with combination of tacrolimus and infliximab. 
Four (44.4%) of the 9 patients achieving remission were negative for CMV-DNA, while 
5 (55.6%) patients undergoing colectomy were positive for CMV-DNA. In all 5 patients 
requiring colectomy, CMV-DNA in the colonic tissue was detected again after IMT.  
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Association between colectomy-free survival and CMV relapse: We evaluated the 
association between the relapse of CMV infection and colectomy-free survival in UC 
patients who were treated with GMA or IMT after 2weeks treatment with ganciclovir. 
Within a median follow up of 21.5 months, 7 patients (25.9%) underwent colectomy. 
Based on Kaplan-Meier analysis, overall cumulative colectomy-free survival was 
estimated to be 53.7% at 65 months. Moreover, we evaluated the difference in 
colectomy-free survival between patients enrolled in this study in whom CMV infection 
was detected again after antiviral therapy [CMV relapse (+)] and those in whom CMV 
infection was not detected [CMV relapse (-)]. As shown in Figure 2, colectomy-free 
survival in the CMV relapse (+) group was estimated to be 12.9% at 65 months, while 
that of CMV relapse (-) group was estimated to be 100% at 60 months. The test 
statistics for the equality of survival distribution were P=0.0243 (log-rank test), 
P=0.0164 (Breslow test) and P=0.0190 (Tarone-Ware test). 
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Discussion 
In this study, we demonstrated that the therapeutic effect of GMA in patients with UC 
was similar to that of IMT, and GMA did not induce the reactivation of CMV. These 
data suggest that GMA could be effective and safe for refractory UC patients positive 
for CMV and help to avoid recurrence of CMV reactivation and infection.  
Previously, it was reported that CMV infection exacerbates UC refractory to IMT and 
the ratio of colectomy and mortality was high in UC patients concomitant with CMV 
infection [11, 12, 13]. In this study, 48.4% of UC patients refractory to IMT were 
diagnosed to be positive for CMV. Interestingly, 25.9% of UC patients positive for 
CMV achieved remission after treatment with antiviral therapy alone, suggesting that 
CMV could be a significant pathogen in some patients with UC refractory to IMT. 
Therefore, it is clinically important to identify UC patients positive for CMV whose 
disease improves with antiviral therapy in future studies. 
Despite the disappearance of CMV-DNA in the colonic mucosa after 2 weeks treatment 
with antiviral therapy, 20 (74.1%) of 27 UC patients did not achieve remission. In these 
patients, it is difficult to judge whether CMV was only a bystander reactivation or 
played a role in exacerbating a UC flare-up by the therapeutic effect of antiviral therapy 
on clinical activity. Our data support the notion that CMV reactivation or infection 
would be associated not only with the use of immunosuppressive drugs, but also with 
UC activity itself. In this regard, we consider anti-inflammatory treatments that will not 
induce CMV reactivation, for UC patients with a history of CMV infection [14]. 
Therefore, we next evaluated the safety and efficacy of GMA for UC patients who 
became negative for CMV after antiviral therapy in comparison with IMT. 
Eleven and 9 patients were treated with GMA and IMT, respectively. As a result, 54.5% 
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(6/11) of the GMA group achieved clinical remission, while 44.4% (4/9) of the IMT 
group achieved remission. Of note, CMV-DNA in the colonic tissue was not detected in 
all patients of the GMA group, while 5 patients of the IMT group became positive for 
CMV after treatment with IMT, who eventually required colectomy. As expected, our 
clinical data suggested that GMA did not affect CMV reactivation because GMA 
theoretically removes granulocytes and monocytes/macrophages in which CMV infects 
latently and reactivates. Immunosuppressants are exogenous factors that influence the 
reactivation of CMV [15]. In this study, four patients who had been treated with IMT 
went into remission and 5 did not, although there was no significant difference in the 
clinical features between patients successfully treated with IMT and those not. Of note, 
all 5 patients who did not achieve remission became positive for CMV despite the 
disappearance of CMV reactivation in the colonic mucosa by antiviral therapy. As 
Domènech et al reported, CMV disease in UC patients occurs in the presence of colonic 
mucosal inflammation and ongoing immunosuppressant therapy [5]. These data 
suggested that if IMT unsuccessfully regulates colonic inflammation, IMT might 
facilitate CMV reactivation in UC patients with a history of CMV reactivation or 
infection and thereby complicate the disease status of UC. Therefore, treatment of UC 
patients with a history of CMV reactivation or infection by IMT requires careful 
follow-up, keeping in mind the possible involvement of CMV infection. Taken together, 
these findings suggest that GMA would be safer for UC patients with a history of CMV 
infection due to the avoidance of CMV reactivation compared with IMT.  
Finally, overall cumulative colectomy-free survival of patients treated with additional 
GMA or IMT after 2weeks antiviral therapy was estimated to be 53.7% at 65 months. 
Colectomy-free survival was significantly different between the CMV relapse (+) group 
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(12.9%) and the CMV relapse (-) group (100%). CMV pathogenicity in IBD patients 
remains controversial. The findings of our study support that CMV infection in patients 
with IBD is associated with a poor prognosis because colectomy-free survival in the 
CMV relapse (+) group was significantly lower than that in the CMV relapse (-) group. 
In this regard, UC treatment should be based on the ability to avoid CMV reactivation 
and infection in patients with refractory UC under IMT, although the pathogenic role of 
CMV in patients with IBD requires further elucidation.  
Is there another therapy for patients with UC positive for CMV? Considering that 
TNF-α plays an important role in reactivation of CMV in both monocytes and dendritic 
cells, infliximab is a potential candidate for UC patients with concomitant CMV 
infection [16, 17]. However, the efficacy of infliximab on UC patients with concomitant 
CMV infection remains controversial because there are few case reports [17, 18].  
In conclusion, GMA is safe and effective for UC patients positive for CMV. GMA alone 
or in combination with antiviral therapy would be a new therapeutic option for UC 
patients with concomitant CMV infection or reactivation, although further studies with 
a larger number of patients are necessary. 
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Figure legends: 
Figure 1. Clinical course of 31 UC patients positive for CMV-DNA in colonic mucosa. 
Shaded rectangular columns with double lines show final outcomes. As for clinical 
outcome of refractory cases to tacrolimus enrolled in this study, all patients refractory to 
tacrolimus positive for CMV-DNA were treated with ganciclovir for 2weeks and 
tacrolimus was completely withdrawn. After the antiviral therapy, one patient went into 
remission. Two were treated with additional GMA, and five were treated with additional 
IMT. As for clinical outcome of refractory cases to cytapheresis, all patients refractory 
to cytapheresis positive for CMV-DNA were treated with ganciclovir for 2weeks and 
cytapheresis was stopped. After antiviral therapy, two of four patients went into 
remission. One was treated with additional GMA Remaining one was treated with 
additional IMT (tacrolimus). 
 
Figure 2. Colectomy free survival of CMV relapse (+) group and CMV relapse (-) 
group. Colectomy free survival of UC patients in whom CMV infection was detected 
again after antiviral therapy (CMV relapse (+)) is depicted by the dash line, and that of 
UC patients in whom CMV infection was not detected (CMV relapse (-)) is depicted by 
the solid line.  
Fig 1 
Fig 2 
Table 1 
